Insulin / insulin-mimetics for performance use
Metabolic Health · Insulin anabolic/metabolic manipulation
Tier D-
High-risk evidence profile
Bottom line
Read Off Label grades Insulin / insulin-mimetics for performance use as D- (2.6/10) based on weak evidence, high benefit magnitude, and a very high-risk safety profile.
Its high-risk evidence profile reflects a Safety score of 0/10; reported benefits and harms can differ by indication, dose, route, duration, and population.
WADA coverage: insulins, insulin-mimetics, S519 and S597.
Studied, labeled, or reported-use context: Clinical diabetes dosing is individualized; no safe non-diabetic performance dose — Rx; WADA S4 prohibited; not individualized guidance.
What the evidence says
WADA coverage: insulins, insulin-mimetics, S519 and S597. Lead evidence here concerns off-label performance use; approved diabetes treatment is a separate clinical context.
Mechanism
Insulin drives glucose and amino-acid storage and is misused in bodybuilding stacks for nutrient partitioning; outside diabetes care the margin for harm is narrow.
Studied, labeled, or reported dose & route
Clinical diabetes dosing is individualized; no safe non-diabetic performance dose
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Insulin / insulin-mimetics for performance use's effects?
- Read Off Label rates the evidence for Insulin / insulin-mimetics for performance use as Weak and the benefit magnitude as high, producing an overall grade of D- (2.6/10). WADA coverage: insulins, insulin-mimetics, S519 and S597.
- What safety findings are reported for Insulin / insulin-mimetics for performance use?
- Insulin / insulin-mimetics for performance use has a very high risk profile in the database. Very High (severe hypoglycemia, seizure, coma, death, weight gain, dosing-error risk) Legal status: Rx; WADA S4 prohibited.
- What does the low Safety score for Insulin / insulin-mimetics for performance use represent?
- The Safety score is 0/10. It records the substantial harms described for one or more use contexts; the Benefit score, indication, dose, route, duration, population, and legal status remain separate parts of the evidence profile.
- What doses or routes are reported for Insulin / insulin-mimetics for performance use?
- Clinical diabetes dosing is individualized; no safe non-diabetic performance dose This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Insulin / insulin-mimetics for performance use work?
- Insulin drives glucose and amino-acid storage and is misused in bodybuilding stacks for nutrient partitioning; outside diabetes care the margin for harm is narrow.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.